Amrita Sarkar

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder

This study identifies PF4 as a central factor in APS by showing it bridges {beta}2GPI to NETs, forming prothrombotic complexes that are targeted by APS antibodies.

Platelet factor 4 modulates endothelial cell antimicrobial activity to enhance bacterial clearance and improve sepsis outcomes

This study identifies platelet factor 4 (PF4) as a mediator of endothelial antimicrobial activity, enhancing bacterial clearance and improving sepsis outcomes through clathrin-mediated endocytosis and reduced immunothrombosis.

G6b-B antibody-based cis-acting platelet receptor inhibitors (CAPRIs) as a new family of anti-thrombotic therapeutics

This study introduces CAPRIs, bispecific antibodies that inhibit platelet activation by clustering G6B with ITAM receptors, showing effectiveness in preventing thrombus formation without causing bleeding.